About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Friday, November 14th, 2014

The QualityStocks
Daily Stock List


US NeuroSurgical, Inc. (USNU)

TopPennyStockMovers, FOX Penny Stocks, Darth Trader, The Stock Psycho, Joe Penny Stocks, StockMister, PennyPickAlerts, PennyStockMoneyTrain, SixFigureStockPicks, WePickPennyStocks, Penny Stock Pick Report, Liquid Tycoon, RisingPennyStocks, Super Hot Penny Stocks, Super Nova Stock Picks, Winning Penny Stock Picks, and Penny Stock Pick Alert reported earlier on US NeuroSurgical, Inc. (USNU), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Founded in 1993, US NeuroSurgical, Inc. is a medical services company with its corporate headquarters in Rockville, Maryland. The Company partners with hospitals and physicians to own and operate facilities employing state-of-the-art and innovative technologies in medical treatment and/or diagnosis. It has successfully developed ventures in medical software, capitated specialty networks, managed care, web-based pharmacy, reproductive endocrinology systems, women's wellness centers, and substance abuse treatment centers. US NeuroSurgical’s shares trade on the OTC Markets’ OTCQB.

The Company owns and operates stereotactic radiosurgery centers that use the gamma knife technology. The gamma knife is a stereotactic radiosurgical device used to treat brain tumors and other malformations of the brain without invasive surgery. U.S. NeuroSurgical is pursuing opportunities in Gamma Knife; IMRT (Intensity Modulated Radiation Therapy); TomoTherapy; Computerized Tomography (CT); Magnetic Resonance Imaging (MRI); Positron Emission Tomography (PET), and Magnetic-Encephalography (MEG).

The Gamma Knife is a 20 ton medical device. Gamma Knife surgery has recognition around the world as the preferred treatment for brain tumors both benign and malignant and for functional diseases of the brain such as arteriovenous malformations, trigeminal neuralgia, tremors, and Parkinson's disease. The Gamma Knife delivers a single, high dose of ionizing radiation emanating from 201 cobalt-60 sources placed about a hemispherical, precision machined cavity. The lesion is initially targeted with precise accuracy using advanced imaging and three dimensional treatment planning such as CT Scans or MR Scans.

Each individual beam is focused on a common target. This produces an intense concentration of radiation at the target site, destroying the lesion while spreading the entry radiation dose uniformly and harmlessly over the patient's skull. Swedish duo, Dr. Lars Leksell of Karolinska Institute and biophysicist Professor Borje Larsson invented the device (however, it is not really a knife) in 1968. Since then over 150,000 patients globally have undergone treatment with the Gamma Knife.

US NeuroSurgical, Inc. (USNU), closed Friday's trading session at $0.3801, down 7.29%, on 13,810 volume with 7 trades. The average volume for the last 60 days is 11,450 and the stock's 52-week low/high is $0.08/$0.46.

GTX Corp. (GTXO)

PennyStocks24, Xtremepicks, OurHotStockPicks, and Pumps and Dumps reported previously on GTX Corp. (GTXO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

OTCQB-listed GTX Corp. is a leading provider of personal location wearable technologies. In addition, the Company is a leader in enterprise 2-way GPS real-time personal location based services. GTX offers a comprehensive end-to-end solution of location based hardware, middleware, apps, connectivity, and professional services. It offers this by way of a strong enterprise platform and licensing business model. Founded in 2002, GTX is based in Los Angeles, California.

GTX also owns and operates LOCiMOBILE, Inc., which develops applications for smart phones and tablets and Code Amber Alertag. The Company owns a broad portfolio of patents, patents pending, registered trademarks, copy rights, and URL's. It has its award-winning patented GPS Smart Shoe, and its’ Smartphone GPS Tracking App.

The Company’s GPS Smart Shoe features a factory installed GPS tracking device embedded in the base of the right heel. The antenna is contained in the back of the heel. Furthermore, the device contains a rechargeable battery. The GPS tracking device in the Shoes sends a signal to a central monitoring station, which uses satellites, a cellular network, and support equipment that relays location coordinates to a tracking website for a user to view.

GPS Shoes contain GPS tracking technology designed to help track individuals afflicted with cognitive disorders including Alzheimer's and other forms of dementia who have a tendency to wander and become lost.  GTX’s Smartphone GPS Tracking App makes finding one’s loved ones easier.

GTX has its Bluetooth Low Energy (BLE) SmartSoles. This is a footwear system design to simply monitor when the wearer enters or leaves a room or a building. Bluetooth Low Energy (BLE) SmartSoles are created for people afflicted with Alzheimer’s, dementia or Autism who are prone to wandering. The BLE SmartSoles look and feel like regular insoles.  

Embedded inside the BLE SmartSoles is a miniaturized Bluetooth low energy chip. It reports when a wearer enters or leaves a pre-set area such as a room or building. The technology is customizable for personal home use or commercial assisted living facilities. The caregiver is alerted through email or text when the wearer leaves the area and can download the free Smart Locator mobile app compatible with Android and Apple devices.

Last month, GTX announced that it officially entered the volume production cycle for its GPS SmartSoles. Expected first delivery is in late December 2014. The GPS SmartSoles are being manufactured in partnership with Atlantic Footcare, Inc. Atlantic Footcare is a leading designer and manufacturer of orthotic insoles for more than two decades. Atlantic is a strategic partner of GTX.

GTX Corp. (GTXO), closed Friday's trading session at $0.0089, down 9.18%, on 884,850 volume with 19 trades. The average volume for the last 60 days is 624,518 and the stock's 52-week low/high is $0.008/$0.045.

HydroPhi Technologies Group, Inc. (HPTG)

The Stock Psycho, Darth Trader, SMS Penny Picks, AwesomeStocks, Psycho Penny Stocks, Wyatt Investment Research, Breaking Bulls, Penny Stock Craze, SuperStockTips, Beacon Equity Research, Stock Preacher, Penny Stocks Finder, InvestorSoup, StockMister, EpicVIP Group, and Epic Stock Picks reported earlier on HydroPhi Technologies Group, Inc. (HPTG), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.

Atlanta, Georgia-based HydroPhi Technologies Group, Inc. is a developer of water-based hydrogen fuel production systems. It develops clean energy technology that delivers improved fuel economy and reduced greenhouse gas emissions. The system uses distilled water for the production of hydrogen and oxygen. This is then injected into the air intake of an engine using carbon-based fuels such as diesel, unleaded gasoline, and natural gas. The Company’s technology isn’t a fuel cell, neither is it a hydrogen alternative to traditional hydrocarbon fuels.

HydroPhi Technologies’ technology is HydroPlant™. This technology has been company tested with resulting reduced vehicle operating costs by way of improved fuel efficiency up to 20 percent, while lowering greenhouse gas emissions up to 70 percent. The technology eliminates the need for high-pressure hydrogen storage or hazardous chemicals while producing a stable, inexpensive alternative fuel source. It does this by using an on-board, on-demand electrolysis system to separate hydrogen and oxygen from water,

The Company offers a real-time monitoring system as part of a hydrogen fuel solution with retrofit capability into standard vehicle engines. Therefore, HydroPhi provides fuel efficiency to a potentially broad spectrum of users. These include logistics, trucking, heavy equipment, marine, as well as agriculture.

Last month, HydroPhi Technologies Europe S.A. (HTE), exclusive European licensee and distributor for HydroPhi Technologies Group, announced the installation of its Hydroplant™ units on vehicles in Poland. Under the agreement executed with Miejskie Przedsiębiorstwo Komunikacyjne Sp z o.o. we Wrocławiu (MPK Wroclaw, Municipal Transport Company in Wroclaw), a large public fleet operator in the second largest city in Poland, the technology is being tested first on two buses from October 15, 2014 and will continue to February 15, 2015.

In addition, in October, HydroPhi Technologies Group announced that its distribution partner, HydroPhi Technologies Europe S.A. (HTE), submitted an application for the European Union's LIFE Program to fund its project called "Demonstration of innovative technology using hydrogen for emissions reduction from engines of heavy duty vehicles." The goal of the project is to develop a state-of-the-art water-based hydrogen catalyst system to improve the efficiency and reduce greenhouse gas emissions of diesel engines on heavy duty trucks and buses in Poland and across Europe.

HydroPhi Technologies Group, Inc. (HPTG), closed Friday's trading session at $0.024, down 4.00%, on 572,097 volume with 33 trades. The average volume for the last 60 days is 536,586 and the stock's 52-week low/high is $0.0065/$0.85.

OxySure Systems, Inc. (OXYS)

PennyStocks24, RedChip, TaglichBrothers, SECFilings.com News, and Vantage Wire reported on OxySure Systems, Inc. (OXYS), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.

OxySure Systems, Inc. is a worldwide leader and medical device innovator of life-saving, easy-to-use emergency oxygen solutions with its "oxygen from powder" technology. A medical technology company, OxySure Systems concentrates on the design, manufacture, and distribution of specialty respiratory and medical solutions. It pioneered a safe and easy-to-use solution to produce medically pure (USP) oxygen from inert powders. OxySure Systems lists on the OTCQB and the Company has its corporate headquarters in Frisco, Texas.

OxySure Systems owns many issued patents and patents pending on the aforementioned technology. This technology makes the provision of emergency oxygen safer, more accessible, and easier to use than traditional oxygen provision systems. The Company’s products improve access to emergency oxygen that affects the survival, recovery, as well as safety of individuals in numerous areas of need.

The proprietary process and methodology is for the emergency/short duration oxygen supply marketplace. With the technology, oxygen is generated on demand and there is no storage of oxygen. Moreover, there are no compressed tanks, dials, valves, or regulatory maintenance. In addition, there is no hydrostatic testing, no batteries, no required training, and none of the hazards associated with traditional oxygen provision systems.

The Company’s launch product utilizing this technology is the OxySure Model 615. This is a portable emergency oxygen device for lay person use. Model 615 bridges the gap between the start of a medical emergency and the time first responders arrive on the scene.

Today, OxySure Systems announced financial and operating results for Q3 2014. For the quarter ended September 30, 2014, revenues increased by 50 percent to $818,456 from $545,820 in Q3 2013. The increase was mainly due to an increase in U.S. product sales and product sales related to military markets.

Gross profit in Q3 2014 was $496,524, up $61,814 or 14 percent from $434,710 in Q3 2013. Gross margin was 60.7 percent. Net loss for the quarter ended September 30, 2014 was $462,349, or $0.02 per share (EBITDA loss: $273,034), versus $82,613 or $0.00 per share for the quarter ended September 30, 2013.

OxySure Systems, Inc. (OXYS), closed Friday's trading session at $0.6399, up 3.21%, on 94,359 volume with 48 trades. The average volume for the last 60 days is 20,572 and the stock's 52-week low/high is $0.4499/$0.90.

KonaRed Corp. (KRED)

PennyStocks24, OTCBB Journal, First Penny Picks, StocksImpossible, PennyStockSpy, 007 Stock Chat, and Greenbackers reported this week on KonaRed Corp. (KRED), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Listed on the OTC Markets’ OTCQB, KonaRed Corp. is the developer of the Hawaiian Coffee Fruit wellness beverage. The Company is in the business of bringing the health and wellness attributes of Hawaiian Coffee fruit to the masses. KonaRed is a premium functional wellness beverage and ingredient enterprise in the developing coffee fruit arena. KonaRed has developed a unique, state-of-the-art, proprietary process. This process produces antioxidant-packed extracts and powders from Hawaiian Coffee Fruit, which are used in KonaRed’s Antioxidant Juices, Organic Green Teas, and On-the-Go Packs. KonaRed has its headquarters in Koloa, Hawaii.

The Company has also developed ingredients that can be added to food, beverages, and nutritional products. KonaRed’s products sell in numerous retail outlets throughout the U.S. and Canada. KonaRed manufactures all-natural antioxidant juices and nutritional supplements from the unique and exclusive Hawaiian CoffeeBerry® - coffee fruit from Kona, Hawaii. Coffee fruit is the fruit surrounding the coffee bean (seed). It was previously discarded as a by-product of coffee production. This fruit has been scientifically recognized as an antioxidant. The 100 percent Pure Hawaiian Coffee Fruit is the ripe red fruit that surrounds the world-renowned Kona coffee bean.

In addition, the Company’s KonaRed Green Tea is made from the prized Hawaiian coffee fruit and enhanced with the wellness attributes of organic green tea. KonaRed Green Tea is available in 10.5 oz. plastic bottles. It is a low-calorie (30 calories per serving), low sugar (6g per serving) wellness beverage.

KonaRed has joined forces with biotech and ingredient supplier powerhouse VDF FutureCeuticals. VDF FutureCeuticals is the owner of the patent-protected CoffeeBerry® coffee fruit technology, a proprietary set of agricultural and industrial processes and a line of distinctive ingredients that capture the potent nutrition inherent in coffee fruit. VDF FutureCeuticals is a leader in the bio-research, development, and manufacture of high-quality fruit, vegetable, and grain-based nutraceutical and functional food ingredients.

Earlier this week, KonaRed announced that it signed a partnership agreement with Dixon Marketing, Inc. Dixon Marketing is a highly respected leader in the military marketplace. Dixon will assist KonaRed in bringing its products to the military market.   

Today, KonaRed announced that its wellness beverages are now available at 978 Kroger family of stores throughout the United States. These include Kroger, Ralphs, Food4Less, and Fred Meyer, among the numerous names well known to shoppers nationwide. KonaRed products available on Kroger shelves are the 10.5 ounce KonaRed Coffeeberry® Original, KonaRed Coffeeberry® with Organic Green Tea, and KonaRed Coffeeberry® with Coconut Water.

KonaRed Corp. (KRED), closed Friday's trading session at $0.285, up 7.55%, on 417,467 volume with 161 trades. The average volume for the last 60 days is 180,965 and the stock's 52-week low/high is $0.22/$1.36.

Titan Pharmaceuticals, Inc. (TTNP)

PennyStocks24, Penny Pick Finders, PennyStockProphet, SecretStockPromo, StockOnion, Planet Penny Stocks, Buzz Stocks, and SmarTrend Newsletters reported earlier on Titan Pharmaceuticals, Inc. (TTNP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Titan Pharmaceuticals, Inc. is a biopharmaceutical company that lists on the OTC Bulletin Board. The Company is developing proprietary therapeutics primarily for the treatment of central nervous system (CNS) disorders. Its chief asset is Probuphine®. This product is the first slow-release implant formulation of buprenorphine hydrochloride (buprenorphine). Probuphine® is the first product to utilize ProNeura™ - a novel, proprietary, long-term drug delivery technology. The ProNeura™ technology has the potential to be used in developing products for the treatment of other chronic conditions, such as Parkinson's disease. Titan Pharmaceuticals is based in South San Francisco, California.

The Probuphine New Drug Application (NDA) was submitted to the U.S. Food and Drug Administration (FDA) in October of 2012 - seeking approval for the treatment of opioid dependence. Titan Pharmaceuticals’ goal is to enter into one or more collaborations with capable pharmaceutical companies to commercialize Probuphine® in the United States and worldwide markets, and to develop, potentially, the product for the treatment of chronic pain.

The design of Probuphine® is to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. A seven-day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011. Probuphine® is an investigational subdermal implant for the maintenance treatment of opioid dependence in adult patients.

In addition, Titan Pharmaceuticals is entitled to royalty revenue of 8-10 percent of net sales of Fanapt® (iloperidone). This is an atypical antipsychotic compound being marketed in the U.S. for the treatment of schizophrenia by Novartis Pharma AG under a sub-license agreement based on a licensed U.S. patent that expires in October 2016 (does not include a possible six month pediatric extension).

In September of this year, Titan Pharmaceuticals announced that patient enrollment in the Phase 3 study of Probuphine®, its investigational subdermal implant for the maintenance treatment of opioid dependence, reached the halfway mark. The Company’s partner, Braeburn Pharmaceuticals, is sponsoring the study. Braeburn expects the study to be fully enrolled before the end of 2014, with study completion on schedule by the middle of 2015. The design of the study is to support resubmission of the New Drug Application for Probuphine with the U.S. FDA, which is expected later in 2015.

This week, Titan Pharmaceuticals reported financial results for the third quarter ended Sept. 30, 2014. The Company generated total revenue in Q3 2014 of approximately $0.9 million, versus approximately $2.2 million in Q3 2013. Revenue earned during the quarters ended Sept. 30, 2014 and 2013 reflects the amortization of the upfront license fee received from development and commercialization partner Braeburn Pharmaceuticals in December 2012.

Net income for Q3 2014 was approximately $0.7 million, or approximately $0.01 per share, versus a net loss of approximately $1.1 million, or approximately $0.01 per share in Q3 2013.

Titan Pharmaceuticals, Inc. (TTNP), closed Friday's trading session at $0.461, up 1.10%, on 221,847 volume with 77 trades. The average volume for the last 60 days is 277,818 and the stock's 52-week low/high is $0.45/$0.91.

Elite Pharmaceuticals, Inc. (ELTP)

Stock Analyzer, PennyStocks24, Pumps and Dumps, Planet Penny Stocks, Buzz Stocks, PennyStockProphet, Penny Pick Finders, StockOnion, SecretStockPromo, Capital Equity Report, OTCBB Journal, First Penny Picks, StocksImpossible, and TheMicrocapNews reported on Elite Pharmaceuticals, Inc. (ELTP), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

OTC Bulletin Board-listed Elite Pharmaceuticals, Inc. develops oral sustained and controlled release products.  The Company also provides contract manufacturing for Ascend Laboratories (a subsidiary of Alkem Laboratories Ltd.). Moreover, it has partnered with Epic Pharma for the manufacturing and distribution of 11 approved products pending manufacturing site, with Hi-Tech Pharmacal to develop an intermediate for a generic product, and a Hong Kong based company to develop a branded product for the U.S. market and its territories. Elite Pharmaceuticals operates a GMP and DEA registered facility for research, development, and manufacturing located in Northvale, New Jersey.

Elite has seven commercial products now being sold, 12 approved products pending manufacturing site transfer, and two additional products under review pending approval by the Food and Drug Administration (FDA). The Company’s lead pipeline products include abuse resistant opioids using Elite’s patented proprietary technology, and a once-daily opioid. They are sustained release oral formulations of opioids for the treatment of chronic pain that address two of the limitations of existing oral opioids: the provision of consistent relief of baseline pain levels and deterrence of potential abuse.

Elite Pharmaceuticals announced this past July the first dosing of a pivotal bioequivalence study in healthy volunteers for ELI-201. This is the Company’s twice daily abuse deterrent oxycodone/naltrexone product, utilizing Elite's proprietary pharmacological abuse deterrent technology. The study is an open-label, single-dose, partially-randomized crossover study in healthy adult subjects.

The primary objective of this study is to compare the bioavailability and establish bioequivalence of ELI-201 controlled-release capsules, 40 mg to OxyContin® controlled-release tablet, 40 mg. The secondary objectives include determining the bioavailability of oxycodone from ELI-201 under fasted and fed conditions and evaluating the safety and tolerability of ELI-201.

In September, Elite Pharmaceuticals reported top line results from a Human Abuse Liability (HAL) study for the ELI-200 product. ELI-200 is an undisclosed abuse deterrent opioid product for pain.

The study results demonstrated statistically significant (p <.0001) lower measures of drug liking, drug high, and good drug effects for the Company’s manipulated (crushed) ELI-200 versus the manipulated (crushed) drug listed comparator product. The study found 91.9 percent of the subjects’ experienced increased drug liking with the comparator product versus ELI-200 in non-dependent recreational drug users when administered intranasally. Furthermore, the study found 80.6 percent of the subjects experienced a decrease in drug liking with the intranasal crushed ELI-200 versus the administration of oral intact ELI-200.

This week, Elite Pharmaceuticals announced that Company management will host a conference call to provide a quarterly business update on Wednesday, November 19, 2014 at 11:00 AM EST. Elite Pharmaceuticals executives will conduct a question and answer session following their remarks.

Elite Pharmaceuticals, Inc. (ELTP), closed Friday's trading session at $0.315, up 5.00%, on 1,005,696 volume with 156 trades. The average volume for the last 60 days is 1,186,072 and the stock's 52-week low/high is $0.09/$0.97.


The QualityStocks
Company Corner


WRIT Media Group, Inc. (WRIT)

The QualityStocks Daily Newsletter would like to spotlight WRIT Media Group, Inc. (WRIT). Today, WRIT Media Group, Inc. closed trading at $0.03, up 50.00%, on 62,327 volume with 5 trades. The stock’s average daily volume over the past 60 days is 55,450, and its 52-week low/high is $0.0107/$0.50.

WRIT Media Group, Inc. (WRIT) is focused on expanding in the digital media industry. The holding company currently operates under two different divisions: content creation via Front Row Networks, and "retro" video gaming via Retro Infinity Inc. and Amiga Games Inc.

The company’s Front Row Networks subsidiary produces, acquires and distributes live concerts in 2D and 3D format for initial worldwide digital broadcast into digitally-enabled movie theaters. In addition to presenting live concerts to massive audiences at lower ticket prices, Front Row Networks will license the content for many different distribution channels and sell merchandize where the live concerts are exhibited. The subsidiary also secures and distributes non-concert alternative theatrical programming and aims to acquire the broadest range of rights for exclusive programming.

Retro Infinity specializes in licensing classic computer and console video game libraries and adapts and republishes the most popular titles for smartphones, modern game consoles, micro-consoles, PCs, and tablets. The company leverages platform and classic game brands, coupled with proprietary technologies, to create new revenue from dormant game libraries.

Amiga Games Inc. shares resources with Retro Infinity to adapt and republish the most popular titles from the Amiga family of computers for smartphones, modern game consoles, micro-consoles, PCs, and tablets. WRIT Media Group leverages the Amiga brand along with game brands of the past and proprietary technologies to create new revenue from classic games that have proven their ability to sell very well.

Together with its subsidiaries, WRIT Media Group is well positioned to benefit from the market growth and increased demand for alternative theatrical, mobile, and interactive content. Disclaimer

WRIT Media Group, Inc. Company Blog

WRIT Media Group, Inc. News:

WRIT Media Group Announces Product Updates and NASCAR Event Recap

Retro Infinity Sponsors NASCAR Driver Carlos Contreras' Record-Breaking 99th Career Race

WRIT Media Group (WRIT) CEO Featured in Exclusive QualityStocks Interview

WordLogic Corp. (WLGC)

The QualityStocks Daily Newsletter would like to spotlight WordLogic Corp. (WLGC). Today, WordLogic Corp. closed trading at $0.072, up 15.20%, on 10,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 46,071, and its 52-week low/high is $0.05/$0.26.

WordLogic Corp. (WLGC) leverages more than 10 years of advanced R&D to assume its position as a global leader in predictive text input technology. Backed by multiple patents and its predictive engine, WordLogic’s interface is revolutionizing the way individuals and businesses search and communicate on touch screen devices. Furthermore, WordLogic offers a range of licensing options of its technology and patent portfolio.

The company’s technology incorporates proprietary Gesturing™ and WordChunking™ features that accelerate typing speeds while reducing the effort needed for accuracy. This interface increased text input on mobile devices by five times, rapidly speeding communication via instant messaging, text messaging, captioning, email and information searching. The iKnowU® keyboard uses state-of-the-art patented technology that becomes more accurate with each use, constantly learning about the user’s style and preferences. Utilizing the WordChunking and Gesturing, iKnowU enables the user to chain together phrases and create whole sentences in a matter of seconds.

For the business realm, WordLogic has developed a unique cloud solution to fit the specific needs of multiple industry sectors, enabling enterprises to create a single cloud-based dictionary specific to the company’s realm of expertise or multiple dictionaries specific for individual specialties or departments. This cloud solution creates continuity for users across multiple devices, boosting accuracy and productivity. WordLogic Reach™ enables users to select and insert meeting plans, contact information, and calendar entries from other apps in the mobile device.

Frost & Sullivan recently recognized WordLogic as the recipient of the 2014 North American Enabling Technology Leadership Award for Predictive Keyboard Applications, saying, “WordLogic’s technically impressive product - WordLogic Predictive Engine and its associated products iKnowU® and Reach™ - offers key competitive advantages, such as market-leading word and phrase prediction capabilities, a context-aware advertising model; simpler integration, increased speed and accuracy; and reduced costs. Add to that the significant number of pending and issued patents and you can see how value a package of technology WordLogic has developed truly is.” Disclaimer

WordLogic Corp. Company Blog

WordLogic Corp. News:

WordLogic the Sale of Exclusive Rights to Legal Enterprise Solutions to Private Equity Group

WordLogic Files Patent Infringement Lawsuit Against TouchType Ltd., Makers of SwiftKey

WordLogic Announces Development of iOS 8 Version of Award-Winning iKnowU Keyboard

Nhale, Inc. (NHLE)

The QualityStocks Daily Newsletter would like to spotlight Nhale, Inc. (NHLE). Today, Nhale, Inc. closed trading at $0.57, up 3.26%, on 141,230 volume with 60 trades. The stock’s average daily volume over the past 60 days is 24,162, and its 52-week low/high is $0.14/$1.33.

Nhale, Inc. (NHLE) develops and sells leading-edge technology in alignment with its mission to become a recognized, premier innovator in cannabis cultivation, dispensaries, testing and scientific products. Nhale explores innovations that will position the company on the front lines of the marijuana revolution.

Nhale is currently aggressively focused on grow operations in states where cannabis is legal, or soon to be legal, such as Oregon, Alaska and Florida. As an increasing number of states move towards legalization for medical or recreational use, growers are positioned to benefit from economies of scale due to escalating demand. Focusing on candidates in the cultivation space, Nhale is poised grow into a successful, sustainable enterprise through product or company acquisition in this explosive space.

Growpod, Nhale’s self-contained grow environment technology, is one of the company’s products and an entry point into the promising cultivation technology space. Growpod uses “controlled environment agriculture” to optimize plant development, plant quality and production efficiency in all climates and seasons.

Nhale believes innovation produces profitability, especially in growth-stage organizations entering emerging industries. This belief guides Nhale’s strong commitment to develop and commercialize cutting-edge consumer-oriented products primed for rapid commercialization. The company has identified strategic industry partnerships to support this growth objective and to secure an increasing footprint in the booming marijuana market. Disclaimer

Nhale, Inc. Company Blog

Nhale, Inc. News:

Nhale (NHLE) Forming Subsidiary Based on Initial Positive Appraisal of Prospective Oregon Grower

Nhale, Inc. (NHLE) Announces Engagement of QualityStocks Investor Relations Services

Oregon Legislation Clears Way for Nhale (NHLE) to Move Towards Definitive Agreement

Falcon Crest Energy (FCEN)

The QualityStocks Daily Newsletter would like to spotlight Falcon Crest Energy (FCEN). Today, Falcon Crest Energy closed trading at $0.0212, up 11.58%, on 9,200 volume with 5 trades. The stock’s average daily volume over the past 60 days is 43,811, and its 52-week low/high is $0.0005/$0.095.

Falcon Crest Energy (FCEN) is a development stage oil and gas exploration and production company focused on developing properties in North America. The company plans to minimize the risk of exploration through development of proved petroleum reserves, and expects to maximize profit through strategic acquisition and liquidation of selected oil and gas properties.

The company specializes in acquiring low risk, high upside properties with substantial exploration potential. Through improvements in oil and gas production technologies, Falcon Crest Energy aims to rapidly increase production levels and generate predictable, sustainable value. The business strategy utilized calls for both 100% acquisitions and joint-ventures to maximize production capacity.

Evergreen Petroleum, a joint venture partner, is working closely with the company to explore oil-bearing formations in Wyoming. Evergreen has conducted and will continue to conduct both regional and local geological studies to define prospects that are worthy of acquiring oil and gas leases. By partnering with industry experts such as Evergreen, Falcon Crest Energy has strategically added extensive technical guidance and field management experience.

Even during challenging times, the world depends on oil & gas exploration and production companies to deliver millions of barrels of oil every day. Increased demand from emerging countries such as China further escalates competition for this precious resource. Backed by an experienced group of professionals, Falcon Crest Energy is well positioned to generate substantial revenues in the short and long term future. Disclaimer

Falcon Crest Energy Company Blog

Falcon Crest Energy News:

Falcon Crest Names Michael Cvetanovic to Advisory Council

Falcon Crest Energy Announces Powder River Basin Leasehold Acquisition

Panther Energy Changes Name to Falcon Crest Energy

Well Power Inc. (WPWR)

The QualityStocks Daily Newsletter would like to spotlight Well Power Inc. (WPWR). Today, Well Power Inc. closed trading at $0.0635, up 4.96%, on 19,719 volume with 9 trades. The stock’s average daily volume over the past 60 days is 134,764, and its 52-week low/high is $0.038/$2.00.

Well Power Inc. (WPWR) has secured the licensing rights to Texas with the first right of refusal on the other US states to a new technology solution to process waste natural gas, such as vented, flared or stranded gas, into “clean power” and engineered fuels, including no-sulphur diesel and diluents. Based on proprietary technology, this solution is mobile, high-yield and can be deployed with minimum capital expenditure.

The company plans to be able to provide its technology with full-service engineering, design, construction, modular fabrication, maintenance and construction management services to clients in the upstream areas of exploration and production. Well Power will also offer consulting services, process assessments, facility appraisals, feasibility studies, technology evaluations, project finance structuring and support, and multi-client subscription services.

Approximately 2.4 million barrels of oil equivalent is wasted each day by gas flaring alone, resulting in $10 billion of lost revenue and 400 million metric tons of CO2 equivalent global greenhouse gas emissions each year. Additionally, environmental degradation associated with gas flaring has been shown to have a significant impact on local populations, often resulting in loss of livelihood and severe health issues.

Well Power’s Micro Refinery Unit (MRU) offers the opportunity to create value from a wasted resource while simultaneously enabling wider access to energy, improved environmental conditions, and economic development for local populations. By eliminating legacy flaring and minimizing new flaring, the company is well positioned to take a leadership role in the ongoing push for sustainable resource development and energy efficiency. Disclaimer

Well Power Inc. Company Blog

Well Power Inc. News:

Well Power - Letter from President to Shareholders

Well Power Inc. to host second webinar on proprietory micro-refinery technology

Well Power Inc. Information to be Available through S&P Capital IQ Corporation Records Program

Ecrypt Technologies, Inc. (ECRY)

The QualityStocks Daily Newsletter would like to spotlight Ecrypt Technologies, Inc. (ECRY). Today, Ecrypt Technologies, Inc. closed trading at $0.136, up 0.74%, on 67,500 volume with 5 trades. The stock’s average daily volume over the past 60 days is 15,358 and its 52-week low/high is $0.09/$0.179.

Ecrypt Technologies, Inc. (ECRY) is an emerging provider of military-strength data security solutions for enterprise, government, and military. The company empowers organizations with the freedom to communicate and collaborate without risk of liability, reputation damage, competitive threat, and other negative outcomes. Ecrypt is the trusted first choice for those looking to keep their communications confidential.

Today’s businesses struggle to guard against the increasing number of dangers as a result of complicated networks built with many different components that are often individually patched to address new threats, while neglecting to close security gaps in traditional solutions. On average, data breaches and subsequent fines and litigation cost a US business $534 million every year, the highest in the world according to the Ponemon Institute.

The flagship Ecrypt solution is an integrated email and encryption server that can be quickly deployed to fortify the security of corporate communication, including attachments and mobile devices, against data breaches while eliminating phishing threats, malware infections, and spam. By using Ecrypt’s paradigm-shifting technology, companies alleviate the need for separate encryption servers with their associated bloated administration and multiple points of weakness.

Ecrypt is well positioned to benefit from increasingly demanding data confidentiality regulations such as the Health Insurance Portability and Accountability Act (HIPAA), the Federal Information Security Management Act (FISMA), and Gramm-Leach-Bliley Act (GLBA). As a result of extensive market research and working directly with organizations in multi-billion dollar industries, the company fully understands the business community’s need to maintain confidentiality, prevent data breaches, comply with government regulations, and mitigate litigation risks. Disclaimer

Ecrypt Technologies, Inc. Blog

Ecrypt Technologies, Inc. News:

Ecrypt Technologies Secures Multi-Year Contract With Global High Tech Manufacturer

Ecrypt Technologies, Inc.'s Chief Executive Officer, Dr. Thomas A. Cellucci, Is Elected to Prestigious NCOIC Board

Ecrypt Technologies, Inc. Appoints Urvashi Mehra as VP of Global Healthcare Solutions

Technology Applications International, Inc. (NUUU)

The QualityStocks Daily Newsletter would like to spotlight Technology Applications International, Inc. (NUUU). Today, Technology Applications International, Inc. closed trading at $1.01, up 1.00%, on 2,033 volume with 3 trades. The stock’s average daily volume over the past 60 days is 2,699, and its 52-week low/high is $0.85/$4.50.

Technology Applications International, Inc. (NUUU) is focused on producing, distributing, marketing and selling skincare products, in addition to engaging in the environmental management and water purification industries. The company conducts its business through two separate wholly owned subsidiaries: Rejuvel Int'l, Inc. and NueEarth, Inc.

Rejuvel Int'l, Inc. developed its skincare line of products using a NASA bioreactor to grow and expand three-dimensional fibroblast cells. Using exclusively licensed technology, licensed from the National Aeronautics and Space Administration and Administrators of the Tulane Educational Fund under U.S. Patent No. 6,730,498, the Rejuvel’s flagship anti-aging facial products trigger the multiplication of human fibroblast skin cells that rebuild skin for a firm, healthy and youthful appearance. The company has been awarded a “seal of approval” from the Space Certification program, setting a new standard for innovation in an industry projected to reach $114 billion in sales by 2015.

NueEarth, Inc. provides environmental management solutions and water purification techniques using a mobile electron beam accelerator unit which creates high-energy electrons that produce free radicals in the wastewater to decompose organic compounds or pollutants. The company has identified a number of different markets for this particle accelerator technology, including the removal of pollutants from wastewater, drinking water, municipal sludge and water that’s contaminated by the fracking process.

Technology Applications International’s management team is methodically establishing its brand in the marketplace with well-respected associations and strategic marketing initiatives. As the company continues to pursue direct consumer sales and other opportunities, it stands to do well with the foundation management has laid for growth. Disclaimer

Technology Applications International, Inc. Company Blog

Technology Applications International, Inc. News:

Rejuvel Int'l, Inc. Will Have its Products Included in Celebrity Gift Bags at the 15th Annual Latin GRAMMY® Awards Show at the MGM Grand in Las Vegas

Rejuvel Int'l, Inc., a Wholly Owned Subsidiary of NUUU, Announced Today the Signing of a Distribution Agreement with Meditem Cyprus Limited

Rejuvel Int'l, Inc., a Wholly Owned Subsidiary of NUUU, Expands its International Branding Efforts with Placements of Multiple Full Page Print Advertisements in International Fashion and Health Magazines


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Real Pennies




Equity Observer

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251